{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-282259","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2023-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.939417+00:00","generated_at":"2026-06-07T22:16:20.772323+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"4D Molecular Therapeutics amends bylaws to update advance notice procedures","bullets":["Board amended and restated bylaws on November 16, 2023.","Amendments update advance notice procedures for business brought before a meeting.","Amendments update advance notice procedures for nominations of directors.","Full text of Amended and Restated Bylaws filed as Exhibit 3.1 with the 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-282259","json":"https://secwatch.observer/filing/0001193125-23-282259.json","markdown":"https://secwatch.observer/filing/0001193125-23-282259.md","text":"https://secwatch.observer/filing/0001193125-23-282259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523282259/0001193125-23-282259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523282259/d797882d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:16:20.772323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c95786c18a68297db4a29fdf84d6be86928f06ce","claim":"4D Molecular Therapeutics, Inc.: Amended and restated bylaws to update advance notice procedures for business brought before a meeting and for nominations of directors (effective 2023-11-16).","evidence_excerpt":"On November 16, 2023, the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc. (the “Company”) amended and restated the Company’s current amended and restated bylaws (the “Amended and Restated Bylaws”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523282259/0001193125-23-282259-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-11-16"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}